A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Public ClinicalTrials.gov record NCT06603220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Study identification
- NCT ID
- NCT06603220
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Evommune, Inc.
- Industry
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- Oral EVO756 300 mg QD Drug
- Oral EVO756 50 mg BID Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 13, 2024
- Primary completion
- May 7, 2025
- Completion
- May 7, 2025
- Last update posted
- May 18, 2026
2024 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cahaba Dermatology & Skin Health Center, LLC | Birmingham | Alabama | 35244 | — |
| California Allergy and Asthma Medical Group | Los Angeles | California | 90025 | — |
| Integrative Skin Science and Research | Sacramento | California | 95815 | — |
| West Dermatology Research Center | San Diego | California | 92121 | — |
| Advanced Clinical Research Institute | Tampa | Florida | 33607 | — |
| Aeroallergy Research Laboratories of Savannah, Inc. | Savannah | Georgia | 31406 | — |
| Treasure Valley Medical Research | Boise | Idaho | 83706 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | — |
| Southern Indiana Clinical Trials | New Albany | Indiana | 47150 | — |
| Indiana Clinical Trials Center, P.C. | Plainfield | Indiana | 46168 | — |
| DelRicht Research | Baton Rouge | Louisiana | 70809 | — |
| Chesapeake Clinical Research, Inc | White Marsh | Maryland | 21162 | — |
| OptiSkin Medical | New York | New York | 10128 | — |
| Red River Research Partners | Fargo | North Dakota | 58013 | — |
| Bexley Dermatology Research | Bexley | Ohio | 43209 | — |
| Allergy, Asthma, and Clinical Research Center | Oklahoma City | Oklahoma | 73120 | — |
| Allergy and Clinical Immunology Associates | Pittsburgh | Pennsylvania | 15241 | — |
| Austin Institute for Clinical Research | Pflugerville | Texas | 78660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06603220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06603220 live on ClinicalTrials.gov.